Scholarlink

<p>This self-controlled prospective study evaluated the efficacy and safety of 450&#xa0;nm blue laser-mediated aminolevulinic acid photodynamic therapy (ALA-BL-PDT) in 28 patients with plaque psoriasis. Participants received four treatment sessions at two-week intervals. At two weeks post-treatment, 67.9% (19/28) achieved Physician Global Assessment (PGA) scores of 0 or 1 (clear or almost clear). Treatment response correlated significantly with baseline disease severity, with higher efficacy observed in patients with body surface area (BSA) ≤ 5% (84.2%) and Psoriasis Area and Severity Index (PASI) ≤ 5 (86.7%) (both <i>p</i> &lt; 0.05). Treatment-associated pain was well-tolerated and decreased significantly after the first session. The one-year recurrence rate among responders was 47.4% (9/19). These preliminary results suggest ALA-BL-PDT may be effective and well-tolerated treatment for mild-to-moderate plaque psoriasis, though larger randomized controlled trials are needed for validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of 450-nm blue laser-mediated aminolevulinic acid photodynamic therapy for plaque psoriasis: a prospective self-controlled clinical trial

  • 期刊论文

  • 发表日期：

    2025年12月8日

查看全文
  • Huihui Tuo,
  • Hengtong Fan,
  • Yan Sun,
  • Yajie Yang,
  • Manyu Ju,
  • Yuhan Xie,
  • Yuqian Wang,
  • Dalin He,
  • Yan Zheng

摘要

This self-controlled prospective study evaluated the efficacy and safety of 450 nm blue laser-mediated aminolevulinic acid photodynamic therapy (ALA-BL-PDT) in 28 patients with plaque psoriasis. Participants received four treatment sessions at two-week intervals. At two weeks post-treatment, 67.9% (19/28) achieved Physician Global Assessment (PGA) scores of 0 or 1 (clear or almost clear). Treatment response correlated significantly with baseline disease severity, with higher efficacy observed in patients with body surface area (BSA) ≤ 5% (84.2%) and Psoriasis Area and Severity Index (PASI) ≤ 5 (86.7%) (both p < 0.05). Treatment-associated pain was well-tolerated and decreased significantly after the first session. The one-year recurrence rate among responders was 47.4% (9/19). These preliminary results suggest ALA-BL-PDT may be effective and well-tolerated treatment for mild-to-moderate plaque psoriasis, though larger randomized controlled trials are needed for validation.